Search
Research
Febrile seizures following measles and varicella vaccines in young children in AustraliaFebrile seizures (FS) are common in childhood with incidence peaking in the second year of life when measles and varicella-containing vaccines are administered.
Research
Association between human rhinovirus C and severity of acute asthma in childrenA new and potentially more pathogenic group of human rhinovirus (HRV), group C (HRVC), has recently been discovered.
News & Events
National guideline to tackle record rates of skin infectionResearchers have developed the first National Healthy Skin Guideline to address record rates of skin infections in Australia’s Indigenous communities.
News & Events
Co-ordinated approach urgently required to slow progression of antibiotic resistanceAboriginal mum and child
News & Events
Pneumococcal vaccine sees hospital admissions for deadly pneumonia slashed by halfThousands of children born in Papua New Guinea (PNG) no longer face a future cut short by severe pneumonia, thanks to the introduction of pneumococcal vaccination as part of the country’s National Immunisation Program.
News & Events
National funding to help foster healthier food environments and fight RHDResearch teams led by The Kids Research Institute Australia have been awarded $3.75 million to support two innovative projects – one focused on pioneering a national ‘Food Atlas’ to map access to healthy and unhealthy food across the country, and the other on developing new ways to prevent Strep throat and rheuma
Research
InfluenzaInfluenza (commonly known as the flu) is caused by a highly contagious virus spread mainly through coughing and sneezing. An annual flu vaccination is the most effective way to prevent flu outbreaks.
News & Events
Childhood influenza vaccination rates improves with better accessMore children across Australia are being vaccinated against the flu since funding was expanded and access widened under the National Immunisation Program
Research
Clinical Management of Staphylococcus aureus Bacteremia in Neonates, Children, and AdolescentsStaphylococcus aureus is a common cause of community and health care-associated bacteremia, with authors of recent studies estimating the incidence of S aureus bacteremia (SAB) in high-income countries between 8 and 26 per 100 000 children per year. Despite this, <300 children worldwide have ever been randomly assigned into clinical trials to assess the efficacy of treatment of SAB.
Research
Effectiveness of nirsevimab in preventing RSV-hospitalisation among young children in Western Australia 2024Respiratory Syncytial Virus (RSV) causes a significant burden of illness for children under 2 years of age. Nirsevimab, a long-acting monoclonal antibody, was registered for RSV prevention in Australia in 2023. In April 2024, Western Australia (WA) launched the country's first state-wide nirsevimab program for all infants and high-risk children entering their second RSV season.